NeuroSense Therapeutics’ (NRSN) Hold Rating Reiterated at Maxim Group

Maxim Group reaffirmed their hold rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a report released on Monday, MarketBeat reports.

NeuroSense Therapeutics Price Performance

Shares of NRSN stock opened at $1.14 on Monday. NeuroSense Therapeutics has a one year low of $0.51 and a one year high of $2.33. The stock has a fifty day moving average price of $1.11 and a 200 day moving average price of $1.03. The stock has a market cap of $15.58 million, a P/E ratio of -1.34 and a beta of 1.38.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) EPS for the quarter.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently raised its position in NeuroSense Therapeutics stock. XTX Topco Ltd increased its stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) by 40.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,996 shares of the company’s stock after buying an additional 13,346 shares during the quarter. XTX Topco Ltd owned 0.34% of NeuroSense Therapeutics worth $58,000 at the end of the most recent reporting period. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.